AU2003236326B2 - A Therapeutic Agent for Impaired Gastric Accommodation - Google Patents

A Therapeutic Agent for Impaired Gastric Accommodation Download PDF

Info

Publication number
AU2003236326B2
AU2003236326B2 AU2003236326A AU2003236326A AU2003236326B2 AU 2003236326 B2 AU2003236326 B2 AU 2003236326B2 AU 2003236326 A AU2003236326 A AU 2003236326A AU 2003236326 A AU2003236326 A AU 2003236326A AU 2003236326 B2 AU2003236326 B2 AU 2003236326B2
Authority
AU
Australia
Prior art keywords
group
compound
addition salt
acid addition
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003236326A
Other languages
English (en)
Other versions
AU2003236326A1 (en
Inventor
Hiroki Kato
Shiro Kobayashi
Yugo Matsunaga
Shigeru Ueki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28786350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003236326(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeria Pharmaceutical Co Ltd filed Critical Zeria Pharmaceutical Co Ltd
Publication of AU2003236326A1 publication Critical patent/AU2003236326A1/en
Application granted granted Critical
Publication of AU2003236326B2 publication Critical patent/AU2003236326B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003236326A 2002-04-08 2003-04-08 A Therapeutic Agent for Impaired Gastric Accommodation Expired AU2003236326B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002104894 2002-04-08
JP2002-104894 2002-04-08
PCT/JP2003/004445 WO2003084537A1 (en) 2002-04-08 2003-04-08 Therapeutic agent for food competence disorder in stomach

Publications (2)

Publication Number Publication Date
AU2003236326A1 AU2003236326A1 (en) 2003-10-20
AU2003236326B2 true AU2003236326B2 (en) 2008-02-28

Family

ID=28786350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003236326A Expired AU2003236326B2 (en) 2002-04-08 2003-04-08 A Therapeutic Agent for Impaired Gastric Accommodation

Country Status (14)

Country Link
US (4) US20050176788A1 (enExample)
EP (2) EP2301540A1 (enExample)
JP (2) JP5281226B2 (enExample)
KR (4) KR20050002925A (enExample)
CN (2) CN1646123A (enExample)
AT (1) ATE522214T1 (enExample)
AU (1) AU2003236326B2 (enExample)
CA (1) CA2481916C (enExample)
CY (1) CY1112057T1 (enExample)
DK (1) DK1493441T3 (enExample)
ES (1) ES2368732T3 (enExample)
PT (1) PT1493441E (enExample)
SI (1) SI1493441T1 (enExample)
WO (1) WO2003084537A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104447612A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 阿考替胺水合物晶型及其制备方法和用途
CN103980226A (zh) * 2014-05-10 2014-08-13 杭州新博思生物医药有限公司 盐酸阿考替胺水合物晶型及其制备方法
CN105315225A (zh) * 2014-07-07 2016-02-10 中美华世通生物医药科技（武汉）有限公司 阿考替胺的酸加成盐及其制备方法
CN104045606B (zh) * 2014-07-11 2015-09-30 杭州新博思生物医药有限公司 一锅法制备阿考替胺盐酸盐的方法
CN109988121B (zh) * 2019-04-28 2023-01-03 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法
AR126442A1 (es) 2021-07-14 2023-10-11 Blueprint Medicines Corp Inhibidores de map4k1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10212271A (ja) * 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
EP0870765A1 (en) * 1995-05-18 1998-10-14 Zeria Pharmaceutical Co., Ltd. Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds
EP0994108A1 (en) * 1997-06-24 2000-04-19 Zeria Pharmaceutical Co., Ltd. Process for producing 2-hydroxybenzamide derivatives
WO2002020010A1 (en) * 2000-09-08 2002-03-14 Zeria Pharmaceutical Co., Ltd. Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
CA2352278A1 (en) * 1998-11-23 2000-06-02 Janssen Pharmaceutica, N.V. Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
MXPA01012330A (es) * 1999-06-02 2002-07-30 Janssen Pharmaceutica Nv Derivados (benzodioxano, benzofurano o benzopirano) aminoalquil sustituidos.
DE60025261T2 (de) * 1999-11-23 2006-08-24 Janssen Pharmaceutica N.V. Verwendung von 5ht3 antagonisten zur fundusentspannung
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US6986882B2 (en) * 2002-01-17 2006-01-17 Astrazeneca Ab Therapy for functional dyspepsia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0870765A1 (en) * 1995-05-18 1998-10-14 Zeria Pharmaceutical Co., Ltd. Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds
JPH10212271A (ja) * 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
EP0994108A1 (en) * 1997-06-24 2000-04-19 Zeria Pharmaceutical Co., Ltd. Process for producing 2-hydroxybenzamide derivatives
WO2002020010A1 (en) * 2000-09-08 2002-03-14 Zeria Pharmaceutical Co., Ltd. Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Japanese Journal of Pharmacology, 2002, vol. 89, no. 4, pp 356-65 *
Journal of Pharmaceutical & Biomedical Analysis, 2001, vol. 25, no. 3-4, pp 599-603 *
Journal of Pharmacology and Experimental Therapeutics, 2000, vol. 294, no. 1, pp 33-7 *
Journal of Smooth Muscle Research, 2000, vol. 36, no. 2, pp 69-81 *

Also Published As

Publication number Publication date
JP2011068692A (ja) 2011-04-07
US20050176788A1 (en) 2005-08-11
CN102125551A (zh) 2011-07-20
AU2003236326A1 (en) 2003-10-20
KR101423284B1 (ko) 2014-07-24
KR20130101162A (ko) 2013-09-12
DK1493441T3 (da) 2011-10-17
KR20050002925A (ko) 2005-01-10
KR20110010837A (ko) 2011-02-07
KR20120037035A (ko) 2012-04-18
JP5360075B2 (ja) 2013-12-04
US20200375954A1 (en) 2020-12-03
CN102125551B (zh) 2015-07-22
ES2368732T3 (es) 2011-11-21
JPWO2003084537A1 (ja) 2005-08-11
JP5281226B2 (ja) 2013-09-04
CA2481916A1 (en) 2003-10-16
SI1493441T1 (sl) 2011-12-30
WO2003084537A1 (en) 2003-10-16
CY1112057T1 (el) 2015-11-04
EP2301540A1 (en) 2011-03-30
EP1493441B1 (en) 2011-08-31
CN1646123A (zh) 2005-07-27
EP1493441A1 (en) 2005-01-05
US20150141475A1 (en) 2015-05-21
EP1493441A4 (en) 2007-10-17
US20090156652A1 (en) 2009-06-18
CA2481916C (en) 2013-02-26
PT1493441E (pt) 2011-09-28
ATE522214T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
US20200375954A1 (en) Therapeutic agent for food competence disorder in stomach
AU679269B2 (en) Treatment of incontinence
JP4415075B2 (ja) 炎症性腸疾患のためのカッパーアヘン製剤作働薬
AU2013237881B2 (en) Dosage forms of halofuginone and methods of use
JP4876367B2 (ja) アミノチアゾール誘導体を有効成分とする大腸運動不全治療剤
JP5101306B2 (ja) 糖尿病治療剤
HUT63055A (en) Process for producing pharmaceutical compositions for relieving diuria
KR101061684B1 (ko) 기능성 장 장애의 치료에서의4-(2-플루오로페닐)-6-메틸-2-(1-피페라지닐)티에노[2,3-디]피리미딘
US8685952B2 (en) Method for the treatment of diabetes
JP5142991B2 (ja) １−（３−クロロフェニル）−３−アルキルピペラジンを含む食欲障害治療用医薬組成物
JPH0753363A (ja) 頻尿治療剤
CA2561293C (en) Treatment of incontinence
JP2025536721A (ja) 強迫性障害の予防または治療のための低用量のドネペジルまたはその誘導体を使用した新規投与レジメン
TW200816995A (en) Pharmaceutical composition containing insulin sensitizers

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ A THERAPEUTIC AGENT FOR IMPAIRED GASTRIC ACCOMMODATION.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: DELETE CO-INVENTORS HIGASHINO, RAITA AND KAWACHI, MASANAO.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAY 2008.

TH Corrigenda

Free format text: IN VOL 22, NO 23, PAGE(S) 2734 UNDER THE HEADING AMENDMENTS -APPLICATION FOR AMENDMENTS DELETE ALL REFERENCE TO 2003236326

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired